The nurse is caring for a client with Hodgkin's Lymphoma who is receiving vincristine for treatment. Which client statement should alert the nurse that the client may be experiencing the most serious adverse effect of vincristine?

Vincristine is a vinca alkaloid antineoplastic agent whose most serious and dose-limiting adverse effect is peripheral neuropathy. The drug binds to tubulin and disrupts microtubule formation, which damages peripheral nerve axons and leads to symptoms such as tingling, numbness, burning, and weakness in the hands and feet — a presentation known as peripheral neuropathy. This is the most serious adverse effect because it can progress to severe motor weakness, autonomic dysfunction, and paralysis if the drug is not dose-adjusted or discontinued. A tingling sensation in the hands and feet is the classic early warning sign of vincristine-induced neurotoxicity and should alert the nurse immediately. Increased urinary frequency is not a hallmark adverse effect of vincristine; the drug can actually cause constipation and urinary retention due to autonomic neuropathy rather than increased frequency. Decreased appetite is a common and expected side effect of most chemotherapy agents but is not specific to vincristine and is not the most serious concern. Hair loss (alopecia) is also a common chemotherapy side effect but is not life-threatening or irreversible in the long term and does not represent the most serious adverse effect of vincristine specifically. The nurse must monitor neurological status closely and report early neuropathy symptoms to the provider.